Novo Nordisk Announces 2027 Price Reduction of Wegovy, Ozempic, Rybelsus

On February 24, 2026, Novo Nordisk announced that the list price of Wegovy injection 2.4 mg and tablets 25 mg, Ozempic injection 0.5, 1, and 2 mg, and Rybelsus tablets 7 and 14 mg will be lowered to $675, effective January 1, 2027.1

The decision applies to all doses of the above medications; however, the company explicitly states that the changes in list price do not impact direct-to-patient, self-pay prices. The price change builds on existing efforts from Novo Nordisk to improve patient access, including self-pay through NovoCare Pharmacy, telehealth initiatives, and more.1

“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States,” Jamey Millar, executive vice president of US operations of Novo Nordisk, said in a statement. “Private and public payers, as well as patients, want access and have been calling for lower list prices. Our actions today answer that call and remove cost barriers so the value of Wegovy and Ozempic can be realized by more patients.”1

Recently, the US Food and Drug Administration (FDA) approved Novo Nordisk’s rebranding of Rybelsus, accepting Ozempic as the proprietary name for the oral semaglutide formulation 1.5, 4, and 9 mg for adults with type 2 diabetes (T2D). The decision was made due to limited patient awareness and use of Rybelsus compared to the following Ozempic has achieved – the pill’s active ingredients are the same, meaning the change was essentially a rebranding of an existing drug. This updated label will be available in the US in Q2 2026.2,3

Semaglutide initially received approval under the name Ozempic to improve blood sugar control in adults with T2D in 2017. Initially only available as an injection of 0.5 or 1 mg, the once-weekly treatment was used as an adjunct to diet and exercise to optimize glycemic control. In 2019, it received approval as a 3 mg, 7 mg, and 14 mg tablet for the same indication under the name Rybelsus in 2019.4

The brand name Wegovy was approved for weight reduction in June of 2021, specifically as 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg injection pens. Rybelsus would subsequently achieve FDA approval for T2D as a 1.5 mg, 4 mg, and 9 mg tablet in 2024, followed by Wegovy being increased to a 1.5 mg, 4 mg, 9 mg, or 25 mg tablet for weight reduction.4

The reported price changes, set to take effect at the start of 2027, reflect Novo Nordisk’s attempts to make all of these semaglutide classifications more accessible to patients and healthcare providers.

“The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs,” Millar said.1

References

1. Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access. February 24, 2026. Accessed February 24, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916504

2. Isaacs D, Bellini N. Novo Nordisk Rebrands Rybelsus as Ozempic to Increase Patient Awareness. HCPLive. February 17, 2026. Accessed February 24, 2026. https://www.hcplive.com/view/novo-nordisk-rebrands-rybelsus-as-ozempic-to-increase-patient-awareness

3. Novo Nordisk. Novo Nordisk introduces Ozempic Pill; Available in the US Q2 2026. February 4, 2026. Accessed February 24, 2026. https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916488

4. Stewart J. Ozempic FDA Approval History. Drugs.com. February 4, 2026. Accessed February 24, 2026. https://www.drugs.com/history/ozempic.html